Iatrogenic	iatrogenic	O	O	O	O
risks	risks	O	O	O	O
of	of	O	O	O	O
endometrial	endometrial	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
after	after	O	O	O	O
treatment	treatment	O	O	O	O
for	for	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
in	in	O	O	O	O
a	a	O	O	O	O
large	large	O	O	O	O
French	french	O	O	O	O
case-control	case-control	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

F	f	O	O	O	O
 	 	O	O	O	O
d	d	O	O	O	O
 	 	O	O	O	O
ration	ration	O	O	O	O
Nationale	nationale	O	O	O	O
des	des	CHEMICALS	O	OTHERS	I
Centres	centres	O	O	O	O
de	de	O	O	O	O
Lutte	lutte	O	O	O	O
Contre	contre	O	O	O	O
le	le	O	O	O	O
Cancer	cancer	O	DISEASE	OTHERS	I
(FNCLCC).Since	(fnclcc).since	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
widely	widely	O	O	O	O
used	used	O	O	O	O
in	in	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
treatment	treatment	O	O	O	O
and	and	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
proposed	proposed	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
prevention	prevention	O	O	O	O
of	of	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
,	,	O	O	O	O
its	its	O	O	O	O
endometrial	endometrial	O	O	O	O
iatrogenic	iatrogenic	O	O	O	O
effects	effects	O	O	O	O
must	must	O	O	O	O
be	be	O	O	O	O
carefully	carefully	O	O	O	O
examined	examined	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
have	have	O	O	O	O
investigated	investigated	O	O	O	O
the	the	O	O	O	O
association	association	O	O	O	O
between	between	O	O	O	O
endometrial	endometrial	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
and	and	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
use	use	O	O	O	O
or	or	O	O	O	O
other	other	O	O	O	O
treatments	treatments	O	O	O	O
in	in	O	O	O	O
women	women	O	O	O	O
treated	treated	O	O	O	O
for	for	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
in	in	O	O	O	O
a	a	O	O	O	O
case-control	case-control	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

Cases	cases	O	O	O	O
of	of	O	O	O	O
endometrial	endometrial	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
diagnosed	diagnosed	O	O	O	O
after	after	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
135	135	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
467	467	O	O	O	O
controls	controls	O	O	O	O
matched	matched	O	O	O	O
for	for	O	O	O	O
age	age	O	O	O	O
,	,	O	O	O	O
year	year	O	O	O	O
of	of	O	O	O	O
diagnosis	diagnosis	O	O	O	O
of	of	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
and	and	O	O	O	O
hospital	hospital	O	O	O	O
and	and	O	O	O	O
survival	survival	O	O	O	O
time	time	O	O	O	O
with	with	O	O	O	O
an	an	O	O	O	O
intact	intact	O	O	O	O
uterus	uterus	O	O	O	O
were	were	O	O	O	O
included	included	O	O	O	O
.	.	O	O	O	O

Women	women	O	O	O	O
who	who	O	O	O	O
had	had	O	O	O	O
received	received	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
were	were	O	O	O	O
significantly	significantly	O	O	O	O
more	more	O	O	O	O
likely	likely	O	O	O	O
to	to	O	O	O	O
have	have	O	O	O	O
endometrial	endometrial	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
diagnosed	diagnosed	O	O	O	O
than	than	O	O	O	O
those	those	O	O	O	O
who	who	O	O	O	O
had	had	O	O	O	O
not	not	O	O	O	O
(	(	O	O	O	O
crude	crude	O	O	O	O
relative	relative	O	O	O	O
risk	risk	O	O	O	O
=	=	O	O	O	O
4.9	4.9	O	O	O	O
,	,	O	O	O	O
p	p	O	O	OTHERS	I
=	=	O	O	O	O
0.0001	0.0001	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Univariate	univariate	O	O	O	O
and	and	O	O	O	O
adjusted	adjusted	O	O	O	O
analyses	analyses	O	O	O	O
showed	showed	O	O	O	O
that	that	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
increased	increased	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
length	length	O	O	O	O
of	of	O	O	O	O
treatment	treatment	O	O	O	O
(	(	O	O	O	O
p	p	O	O	OTHERS	I
=	=	O	O	O	O
0.0001	0.0001	O	O	O	O
)	)	O	O	O	O
or	or	O	O	O	O
the	the	O	O	O	O
cumulative	cumulative	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
received	received	O	O	O	O
(	(	O	O	O	O
p	p	O	O	OTHERS	I
=	=	O	O	O	O
0.0001	0.0001	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
irrespective	irrespective	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
daily	daily	O	O	O	O
dose	dose	O	O	O	O
.	.	O	O	O	O

Women	women	O	O	O	O
who	who	O	O	O	O
had	had	O	O	O	O
undergone	undergone	O	O	O	O
pelvic	pelvic	O	O	O	O
radiotherapy	radiotherapy	O	O	O	O
also	also	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
higher	higher	O	O	O	O
risk	risk	O	O	O	O
(	(	O	O	O	O
crude	crude	O	O	O	O
relative	relative	O	O	O	O
risk	risk	O	O	O	O
=	=	O	O	O	O
7.8	7.8	O	O	O	O
,	,	O	O	O	O
p	p	O	O	OTHERS	I
=	=	O	O	O	O
0.0001	0.0001	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

After	after	O	O	O	O
adjusting	adjusting	O	O	O	O
for	for	O	O	O	O
confounding	confounding	O	O	O	O
factors	factors	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
was	was	O	O	O	O
higher	higher	O	O	O	O
for	for	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
users	users	O	O	O	O
(	(	O	O	O	O
p	p	O	O	OTHERS	I
=	=	O	O	O	O
0.0012	0.0012	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
treatment	treatment	O	O	O	O
for	for	O	O	O	O
more	more	O	O	O	O
than	than	O	O	O	O
3	3	O	O	O	O
years	years	O	O	O	O
(	(	O	O	O	O
all	all	O	O	O	O
p	p	O	O	OTHERS	I
<	<	O	O	O	O
0.03	0.03	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
pelvic	pelvic	O	O	O	O
radiotherapy	radiotherapy	O	O	O	O
(	(	O	O	O	O
p	p	O	O	OTHERS	I
=	=	O	O	O	O
0.012	0.012	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Women	women	O	O	O	O
who	who	O	O	O	O
had	had	O	O	O	O
endometrial	endometrial	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
and	and	O	O	O	O
had	had	O	O	O	O
received	received	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
had	had	O	O	O	O
more	more	O	O	O	O
advanced	advanced	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
and	and	O	O	O	O
poorer	poorer	O	O	O	O
prognosis	prognosis	O	O	O	O
than	than	O	O	O	O
those	those	O	O	O	O
with	with	O	O	O	O
endometrial	endometrial	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
who	who	O	O	O	O
had	had	O	O	O	O
not	not	O	O	O	O
received	received	O	O	O	O
this	this	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

Our	our	O	O	O	O
results	results	O	O	O	O
suggest	suggest	O	O	O	O
a	a	O	O	O	O
causal	causal	O	O	O	O
role	role	O	O	O	O
of	of	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
endometrial	endometrial	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
,	,	O	O	O	O
particularly	particularly	O	O	O	O
when	when	O	O	O	O
used	used	O	O	O	O
as	as	O	O	O	O
currently	currently	O	O	O	O
proposed	proposed	O	O	O	O
for	for	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
prevention	prevention	O	O	O	O
.	.	O	O	O	O

Pelvic	pelvic	O	O	O	O
radiotherapy	radiotherapy	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
an	an	O	O	O	O
additional	additional	O	O	O	O
iatrogenic	iatrogenic	O	O	O	O
factor	factor	O	O	O	O
for	for	O	O	O	O
women	women	O	O	O	O
with	with	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Endometrial	endometrial	O	O	OTHERS	I
cancers	cancers	O	DISEASE	OTHERS	I
diagnosed	diagnosed	O	O	O	O
in	in	O	O	O	O
women	women	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
have	have	O	O	O	O
poorer	poorer	O	O	O	O
prognosis	prognosis	O	O	O	O
.	.	O	O	O	O

Women	women	O	O	O	O
who	who	O	O	O	O
receive	receive	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
should	should	O	O	O	O
be	be	O	O	O	O
offered	offered	O	O	O	O
gynaecological	gynaecological	O	O	O	O
surveillance	surveillance	O	O	O	O
during	during	O	O	O	O
and	and	O	O	O	O
after	after	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
long-term	long-term	O	O	O	O
evaluation	evaluation	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
risk-benefit	risk-benefit	O	O	O	O
ratio	ratio	O	O	O	O
of	of	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
as	as	O	O	O	O
a	a	O	O	O	O
preventive	preventive	O	O	O	O
treatment	treatment	O	O	O	O
for	for	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
is	is	O	O	O	O
clearly	clearly	O	O	O	O
warranted	warranted	O	O	O	O
.	.	O	O	O	O

